Oculis
Dr. Jacobs brings to Oculis more than 20 years of leadership experience in drug development. He joins us from Osmotica Pharmaceuticals, where he was Vice-President of Clinical Development and Medical Affairs since 2017. During his tenure, in addition to leading the clinical programs from phase I to IV in several therapeutic areas including ophthalmology, he was a key contributor to successful FDA submissions and market approvals, a key experience. Prior to his role at Osmotica, Dr. Jacobs held drug development leadership roles at Daiichi-Sankyo Pharmaceuticals, Aptalis Pharmaceuticals, Johnson & Johnson and King Pharmaceuticals.
This person is not in any offices
Oculis
1 followers
Oculis is a clinical stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back-and front-of-the-eye in order to improve the sight and the lives of patients worldwide.